Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
irinotecan hydrochloride
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XX19
|
| gptkbp:brand |
gptkb:irinotecan
|
| https://www.w3.org/2000/01/rdf-schema#label |
Camptosar
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:mechanismOfAction |
topoisomerase I inhibitor
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea neutropenia |
| gptkbp:usedFor |
gptkb:cancer
colorectal cancer |
| gptkbp:bfsParent |
gptkb:irinotecan
|
| gptkbp:bfsLayer |
7
|